Restriction of which electrolyte is recommended in the management of high blood pressure?

Choice A reason: ACE inhibitors do not lower heart rate. They lower blood pressure by blocking the conversion of angiotensin I to angiotensin II, which is a potent vasoconstrictor. Beta blockers are the drugs that lower heart rate and blood pressure.

Choice B reason: ACE inhibitors inhibit vasoconstriction. This is the correct statement that describes the action of these medications. By blocking the angiotensin II formation, they prevent the narrowing of the blood vessels and reduce the resistance to blood flow.

Choice C reason: ACE inhibitors do not increase aldosterone secretion. They decrease it. Aldosterone is a hormone that causes the kidneys to retain sodium and water, which increases blood volume and pressure. By blocking the angiotensin II formation, ACE inhibitors reduce the stimulation of aldosterone secretion and promote sodium and water excretion.

Choice D reason: ACE inhibitors do not promote sodium retention. They promote sodium excretion. As explained above, ACE inhibitors reduce the aldosterone secretion and prevent the kidneys from reabsorbing sodium and water. This lowers the blood volume and pressure.

Choice A reason: Montelukast does not increase vessel permeability. It blocks the effects of leukotrienes, which are inflammatory mediators that cause vessel permeability, bronchoconstriction, and mucus secretion. By blocking leukotrienes, montelukast reduces vessel permeability and inflammation.

Choice B reason: Montelukast reduces bronchoconstriction and mucus secretion. It blocks the effects of leukotrienes, which are inflammatory mediators that cause bronchoconstriction and mucus secretion. By blocking leukotrienes, montelukast improves airflow and reduces asthma symptoms.

Choice C reason: Montelukast does not increase inflammation. It blocks the effects of leukotrienes, which are inflammatory mediators that cause inflammation, bronchoconstriction, and mucus secretion. By blocking leukotrienes, montelukast reduces inflammation and prevents asthma exacerbations.

Choice D reason: Montelukast does not increase bronchoconstriction. It blocks the effects of leukotrienes, which are inflammatory mediators that cause bronchoconstriction, mucus secretion, and inflammation. By blocking leukotrienes, montelukast reduces bronchoconstriction and improves airflow.